Galectin Therapeutics

Galectin Therapeutics is excited to announce it has just launched its website for its clinical trial, NAVIGATE Study. Now both #patients and #physicians can find information on #NASH cirrhosis through resources found on the site. Visit here https://navigatenash.com/

"Given the current challenging environment, I am proud of our success, highlighted by site activations and ongoing enrollment of our innovative NAVIGATE study," said Joel Lewis, CEO & President of Galectin Therapeutics. Read the full fiscal 2020 financial results and business update here https://bit.ly/3szWBtQ

In a recent article from AARP, author Jeanne Lenzer recounts Cesar Alvarez's experience as a patient with NAFLD (early-stage #NASH) and his diagnosis with the condition. Read the article here http://bit.ly/2OYC1ot

It’s National #NutritionMonth and Galectin Therapeutics wanted to remind you of a few foods that promote healthy #liver function.

"Galectin-3 acts as a glue and promotes cell to cell interaction and cell to cell metric interaction, by doing so, galectin-3 brings all the actors of inflammation and fibrosis together," says Dr. Pol F. Boudes, M.D., CMO of Galectin Therapeutics. Watch the full presentation from H.C. Wainwright Global Life Sciences Conference here https://bit.ly/3qfEvLL #NASH cirrhosis

Have you ever wondered what foods you should avoid to maintain a healthy #liver? #LiverAwarenessMonth

#DYK women are more likely to have #NASH than men? Also, most patients with this chronic #liver disease are between the ages of 40 and 60. To learn more about NASH and other liver diseases, read here: https://bit.ly/357b3iq #LiverAwarenessMonth

According to the CDC, over 40,000 U.S. adults die a year from chronic #liver diseases such as #NASH Cirrhosis. Find more important statistics here: https://bit.ly/33AKqTE #NationalLiverAwarenessMonth

In a recent study published in the American Journal of Gastroenterology, researchers found that women with hepatocellular carcinoma (HCC) are more likely to have early-stage #NASH than men. Read more here: https://bit.ly/33IZRZW

#DYK the #liver is the largest solid organ in the body, reaching the size of a rugby ball? Not only is it the largest organ, but it also has over 500 functions such as breaking down food to convert into energy, fighting infections, and changing potentially damaging substances. https://bit.ly/36Rg0OK #NationalLiverAwarenessMonth

During October, Galectin Therapeutics will be providing you with information on your #liver and how to maintain its health for #NationalLiverAwarenessMonth. Learn more about what Galectin Therapeutics does here: https://bit.ly/3caeVAE

In the U.S., every 1 in 5 children is overweight or obese. As one of the major factors in developing #NASH is obesity, early-stage NASH, or #NAFLD is the most common form of liver disease in children. Learn more here: https://bit.ly/2Fnyw62

Today at 4:00 p.m. EDT, Galectin Therapeutics will be hosting an investor webinar where they will share key insights into the Company's recent developments and upcoming milestones. Join here: https://bit.ly/3muwNgb

Researchers from the University of California, San Diego conducted a study on high fructose intake and how it may increase the risk of early-stage #NASH. Read the important findings here: https://bit.ly/2FLMLle

On Tuesday, September 29 at 4:00 p.m. EDT, Galectin Therapeutics' management team will share important insights into the Company's recent developments and upcoming milestones during an investor webinar. Click here to learn more: https://bit.ly/3ct9M8Q

Published in Healio, a top publication for medical news, Dr. Pol Boudes, CMO of Galectin Therapeutics, and former CEO and member of the board of directors, Dr. Harold Shlevin discusses Galectin Therapeutics' phase 2b/3 clinical trial of belapectin to treat cirrhosis in patients with #NASH. Read it here: https://bit.ly/3k5nQYL

At the H.C. Wainwright 22nd Annual Virtual Global Investment Conference, Galectin Therapeutics presented an overview and the milestones of its NASH-RX clinical trial. Read the full presentation here: https://bit.ly/35D8SoI

Today at 12:30 p.m. EDT, Galectin Therapeutics will be presenting at the H.C. Wainwright 22nd Annual Virtual Conference. Register here: https://bit.ly/3hlTY8v